Investing in Array Technologies, Inc. (ARRY)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)0.50-96
Intrinsic value (DCF)0.50-96
Graham-Dodd Method0.00-100
Graham Formula8.37-35

Company description

Array BioPharma Inc. (NASDAQ: ARRY) is a leading biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases. Founded in 1998, the company has become a pioneer in the field of targeted therapy, utilizing its expertise in chemistry, biology, and drug development to create potent and selective drugs that specifically target the underlying mechanisms of disease. Array BioPharma has a robust pipeline of innovative drug candidates, including both small molecule inhibitors and immuno-oncology therapies, targeting a variety of solid tumors and hematologic malignancies. The company's flagship product, BRAFTOVI® (encorafenib), in combination with MEKTOVI® (binimetinib), has been approved by the FDA for the treatment of advanced melanoma with a BRAF mutation, and is currently being investigated for the treatment of other types of cancer. With a strong commitment to scientific excellence and patient-driven research, Array BioPharma has established collaborations with leading academic institutions, biotechnology and pharmaceutical companies, and government agencies around the world. The company's team of passionate and dedicated employees, together with its innovative technology platforms, have enabled Array to advance its drug candidates quickly and efficiently through clinical trials. Array is also committed to making a positive impact in the community through various corporate social responsibility initiatives, including charitable donations, volunteerism, and environmental sustainability efforts. In addition, the company places